ANDA 88004, held by Mylan. Thioridazine Hydrochloride.
As of Nov 16, 2026, ANDA 88004 (Thioridazine Hydrochloride), held by Mylan, was first approved by FDA on Nov 18, 1983, with 27 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 1983 | Original application | Approved | None posted |
| Thioridazine Hydrochloride100MG · tablet;oral | Thioridazine Hydrochloride | Rx |
| Thioridazine Hydrochloride10MG · tablet;oral | Thioridazine Hydrochloride | Rx |
| Thioridazine Hydrochloride25MG · tablet;oral | Thioridazine Hydrochloride | Rx |
| Thioridazine Hydrochloride50MG · tablet;oral | Thioridazine Hydrochloride | Rx |
| Jan 22, 2025 | Supplement 47Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 38Labeling · Standard review | Approved | None posted |
| Dec 3, 2010 | Supplement 35Labeling | Approved | None posted |
| Jun 12, 2009 | Supplement 34Labeling | Approved | None posted |
| Jan 23, 2009 | Supplement 33Labeling | Approved | None posted |
| Apr 25, 2008 | Supplement 31Manufacturing | Approved | None posted |
| Sep 5, 2002 | Supplement 27Labeling | Approved | None posted |
| Aug 14, 2001 | Supplement 26Labeling | Approved | None posted |
| Feb 25, 1998 | Supplement 24Manufacturing | Approved | None posted |
| Feb 5, 1998 | Supplement 25Manufacturing | Approved | None posted |
| Feb 24, 1997 | Supplement 23Manufacturing | Approved | None posted |
| Sep 15, 1993 | Supplement 22Manufacturing | Approved | None posted |
| May 31, 1991 | Supplement 20Labeling | Approved | None posted |
| May 17, 1991 | Supplement 19Labeling | Approved | None posted |
| Dec 20, 1990 | Supplement 14Manufacturing | Approved | None posted |
| Dec 20, 1990 | Supplement 13Manufacturing | Approved | None posted |
| Oct 31, 1990 | Supplement 18Labeling | Approved | None posted |
| Mar 30, 1990 | Supplement 17Labeling | Approved | None posted |
| Jan 4, 1990 | Supplement 49Labeling | Approved | None posted |
| Jan 4, 1990 | Supplement 16Labeling | Approved | None posted |
| Mar 29, 1989 | Supplement 15Bioequivalence | Approved | None posted |
| May 20, 1988 | Supplement 12Labeling | Approved | None posted |
| May 20, 1988 | Supplement 10Labeling | Approved | None posted |
| May 6, 1988 | Supplement 11Manufacturing | Approved | None posted |
| May 28, 1985 | Supplement 1Manufacturing | Approved | None posted |
| Jul 3, 1984 | Supplement 3Manufacturing | Approved | None posted |
| Apr 10, 1984 | Supplement 4Manufacturing | Approved | None posted |
| Nov 18, 1983 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters